SCHEMBL26078326

SCHEMBL26078326

Clc1ccc(CC2=NCCN2)cc1-c1cn[nH]c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ADRA1D P25100 4/20 0.50
▸ ADRA1A P35348 4/20 0.50
▸ ADRA1B P35368 4/20 0.50
▸ TAAR1 Q96RJ0 4/20 0.47
▸ CYP2D6 P10635 3/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ HTR1D P28221 6/20 0.45
▸ HTR1B P28222 5/20 0.45
▸ ADRA2A P08913 3/20 0.43
▸ ADRA2B P18089 3/20 0.43
▸ ADRA2C P18825 3/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ PTGIR P43119 1/20 0.40
▸ RAD52 P43351 1/20 0.40
▸ HIF1A Q16665 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL953553 0.77 TAAR1 (0.60) ADRA1DADRA1AADRA1BTAAR1CYP2D6
SCHEMBL26078334 0.74 HTR1D (0.49) ADRA1DADRA1AADRA1BTAAR1CYP2D6
SCHEMBL26078327 0.73 ADRA1A (0.50) ADRA1DADRA1AADRA1BTAAR1CYP2D6
SCHEMBL26078328 0.72 ADRA1A (0.51) ADRA1DADRA1AADRA1BTAAR1CYP2D6
SCHEMBL26078476 0.72 TAAR1 (0.41) ADRA1DADRA1AADRA1BTAAR1CYP2D6
SCHEMBL26078323 0.71 ADRA1A (0.56) ADRA1DADRA1AADRA1BTAAR1CYP2D6
SCHEMBL4986025 0.71 TAAR1 (0.56) ADRA1DADRA1AADRA1BTAAR1CYP2D6
SCHEMBL26078318 0.70 ADRA1A (0.51) ADRA1DADRA1AADRA1BTAAR1CYP2D6
SCHEMBL4629679 0.69 TAAR1 (0.76) ADRA1DADRA1AADRA1BTAAR1CYP2D6
SCHEMBL2869241 0.69 HTR1D (0.69) ADRA1DADRA1AADRA1BTAAR1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE CURASEN THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE CURASEN THERAPEUTICS, INC. 2023-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312524-A1 ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE ADRA1A, ADRB1, ADRA1D ADRA1D 3/4885ADRA1A 1/4885ADRA1B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback